Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03970148
Other study ID # 2181-147-01/06/M.S.-19-2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 2, 2019
Est. completion date December 30, 2020

Study information

Verified date June 2019
Source University Hospital of Split
Contact Ljubo Znaor, MD, PHD
Phone +385915052181
Email ljuboznaor@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vitreous fluid, containing 95% water, fills the space behind the lens. Its gelatinous consistency is due to the presence of hyaluronic acid, mucopolysaccharide and collagen fibers. With age, the collagen aggregates into parallel bundles, bound by cross links, leaving the pockets of liquid in the glass body. This redistribution is referred to as syneresis, which is found in 90% older than 40 years. After liquefaction, the vitreous enters the retroviral space and separates the posterior hyaloid membrane from the retina. When separating from the optical disk it forms an annular formation (Weiss ring) in front of the optical disc. These agglomerated collagen bundles (opacities) disperse the photons of light and are perceived by the patients as a "gray silhouette-like artifact". Two major interventions for these symptoms include Nd: YAG laser vitreolysis and vitrectomy. The less invasive method Nd: YAG laser increases the temperature of the opacity thus vaporizing them to smaller fragments that are easier to sediment onto the bottom of the vitreous cavity thereby relieving the symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 30, 2020
Est. primary completion date October 2, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18 years or older

- Is able to give written informed consent to the procedure

- Patients with clinical symptoms of floaters and clinically confirmed diagnosis of opacity in the vitreous body.

Exclusion Criteria:

- Inability to tolerate the procedure

- Blurred anterior eye segment

- Cataract or Intraocular lens opacity

- Blurred posterior eye segment

- Active eye inflammation

- Iris synechiae

- Uncontrolled intraocular pressure elevation

- Peripheral retinal degeneration

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Nd: YAG laser
Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.

Locations

Country Name City State
Croatia University Hospital of Split Split Hrvatska

Sponsors (2)

Lead Sponsor Collaborator
University Hospital of Split University of Split, School of Medicine

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with resolution of symptoms Number of patients who reported resolution of symptoms after the treatment 1 month
Secondary Macular Oedema Development rate Rate of macular oedema development after the treatment 1 month
Secondary Rate of treatment side effects Rate of treatment side effects such as: retinal damage, retinal detachment, cataract... 1 month
Secondary Retreatment rate Number of treatment sessions needed for simptom resolution 1 month
See also
  Status Clinical Trial Phase
Completed NCT04865991 - Comparison of Propofol Target Controlled Infusion (TCI) and Sevoflurane N/A
Not yet recruiting NCT04346095 - Oral Sedation in Vitreoretinal Surgery Phase 4
Completed NCT00198471 - Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Phase 2
Completed NCT05249413 - Early Vitrectomy for Endophthalmitis After Cataract Surgery
Terminated NCT02783209 - Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient N/A